These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 30691373)
1. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Rowe SP; Gorin MA; Pomper MG Annu Rev Med; 2019 Jan; 70():461-477. PubMed ID: 30691373 [TBL] [Abstract][Full Text] [Related]
2. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743 [TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Arsenault F; Beauregard JM; Pouliot F Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893 [TBL] [Abstract][Full Text] [Related]
6. Imaging of Prostate-Specific Membrane Antigen Using [ Rowe SP; Gorin MA; Pomper MG PET Clin; 2017 Jul; 12(3):289-296. PubMed ID: 28576167 [TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581 [TBL] [Abstract][Full Text] [Related]
8. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy. Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588 [TBL] [Abstract][Full Text] [Related]
9. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071 [TBL] [Abstract][Full Text] [Related]
10. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Shakespeare TP Radiat Oncol; 2015 Nov; 10():233. PubMed ID: 26582424 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, Predictive Factors, and Prediction Nomograms for Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059 [TBL] [Abstract][Full Text] [Related]
12. [The role of PSMA PET-CT in patients with metastatic prostate cancer]. von Hardenberg J; Büsing KA; Nuhn P; Ritter M Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045 [TBL] [Abstract][Full Text] [Related]
13. [ Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797 [TBL] [Abstract][Full Text] [Related]
14. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. Ceci F; Castellucci P; Fanti S Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482 [TBL] [Abstract][Full Text] [Related]
15. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920 [TBL] [Abstract][Full Text] [Related]
16. PSMA PET and Radionuclide Therapy in Prostate Cancer. Bouchelouche K; Turkbey B; Choyke PL Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432 [TBL] [Abstract][Full Text] [Related]
17. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Mease RC; Foss CA; Pomper MG Curr Top Med Chem; 2013; 13(8):951-62. PubMed ID: 23590171 [TBL] [Abstract][Full Text] [Related]
18. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956 [No Abstract] [Full Text] [Related]
19. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer]. Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428 [TBL] [Abstract][Full Text] [Related]
20. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]